ReviewNutrients2026
Linking Obesity and Depression Through the Gut-Brain Axis: The Impact of Short-Chain Fatty Acids and Inflammation.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psyllium and Glucomannan as Viscous Fiber Modulators of the Gut-Microbiome-Incretin Axis: Molecular Links to Metabolic Inflammation, Barrier Function, and GLP-1 Receptor Agonist Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major public health problem that puts pressure on healthcare systems globally. The purpose of this narrative review is to summarize and analyse recent research on the bidirectional link between obesity and mental health, focusing on the biological, behavioural, dietary, emotional, and metabolic mechanisms arising from gut microbiota interactions. Epidemiological association between obesity and mental health disorders, especially depression and anxiety, often occurs bidirectionally, reinforcing each other. Low-grade systemic inflammation is a condition typically found in obesity, being a fundamental element of neuropsychiatric disorders. Considered the main energy substrate for colon cells, SCFAs are synthesized in the intestine and exert important local effects by reducing both local and systemic inflammation. The intestinal microbiota maintains this homeostasis through the SCFAs it produces. The combined impact of the increased intestinal permeability, immune activation, and disrupted metabolism of SCFAs and tryptophan contributes to the onset and progression of depression and anxiety, as well as to significant cognitive dysfunction, especially in obese individuals. Understanding the mechanisms by which microbiota metabolites influence brain development, neuroplasticity, and behaviour could pave the way for new and innovative therapeutic strategies for the treatment of obesity and depression. Conclusions: The association of these pathologies is not coincidental, as they coexist through overlapping biological pathways that they partially or completely share. The main pathway involved is formed by the brain-gut axis and its mediators (SCFAs).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.